First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH – Get Free Report) was the target of a significant increase in short interest in the month of October. As of October 15th, there was short interest totalling 1,500 shares, an increase of 200.0% from the September 30th total of 500 shares. Based on an average daily volume of 3,900 shares, the short-interest ratio is presently 0.4 days.
First Trust Nasdaq Pharmaceuticals ETF Trading Down 0.7 %
Shares of FTXH traded down $0.18 during trading hours on Friday, reaching $27.96. 2,368 shares of the company traded hands, compared to its average volume of 5,520. The stock’s fifty day moving average price is $28.93 and its 200 day moving average price is $27.83. The firm has a market cap of $16.78 million, a price-to-earnings ratio of 15.98 and a beta of 0.70. First Trust Nasdaq Pharmaceuticals ETF has a 12-month low of $23.85 and a 12-month high of $29.72.
First Trust Nasdaq Pharmaceuticals ETF Cuts Dividend
The business also recently disclosed a quarterly dividend, which was paid on Monday, September 30th. Shareholders of record on Thursday, September 26th were given a $0.1218 dividend. The ex-dividend date was Thursday, September 26th. This represents a $0.49 annualized dividend and a yield of 1.74%.
Hedge Funds Weigh In On First Trust Nasdaq Pharmaceuticals ETF
About First Trust Nasdaq Pharmaceuticals ETF
The First Trust Nasdaq Pharmaceuticals ETF (FTXH) is an exchange-traded fund that is based on the Nasdaq US Smart Pharmaceuticals index. The fund tracks the 30 most liquid US pharmaceutical companies, weighted according to factors related to value, volatility, and growth. FTXH was launched on Sep 20, 2016 and is managed by First Trust.
Featured Stories
- Five stocks we like better than First Trust Nasdaq Pharmaceuticals ETF
- Following Congress Stock Trades
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- How to Use the MarketBeat Excel Dividend Calculator
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for First Trust Nasdaq Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for First Trust Nasdaq Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.